Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels
Vernadsky National Library of Ukraine
Переглянути архів Інформація| Поле | Співвідношення | |
| Title |
Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels
|
|
| Creator |
Rivkina, A.
Vitols, G. Murovska, M. Lejniece, S. |
|
| Subject |
Original contributions
|
|
| Description |
Serum thymidine kinase (TK), zeta-associated protein of 70 kDa (ZAP-70) and CD38 levels have been shown to be correlated with survival in chronic lymphocytic leukaemia (CLL). Aim: To investigate the possible correlations between TK, ZAP-70 and CD38 levels as prognostic markers in new diagnosed Rai stages of CLL patients. Methods: 120 CLL patients were enrolled. ELISA was used to measure serum TK level, flow cytomerty — to determine ZAP-70 and CD38 expression applying ZAP-70 Kit and monoclonal antibody to CD38, respectively. Results: Significantly higher levels of TK were found in the high progression group of CLL patients that corresponded to stage II (Rai classification). An elevated level of TK, CD38 and ZAP-70 together was also found in the II stage. The coefficient of correlation between CD38 and ZAP-70 is reliable (p < 0.001). There is also a correlation between the level of TK and the disease stage (p < 0.05). Other parameters do not show this correlation. Conclusion: The determination of TK, ZAP-70 and CD38 together allows patients susceptible to a possible stage of the disease, to be identified. Estimation of the factors at an early stage of the disease may allow an earlier commencement of treatment.
|
|
| Date |
2018-06-19T10:43:08Z
2018-06-19T10:43:08Z 2011 |
|
| Type |
Article
|
|
| Identifier |
Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels / A. Rivkina, G. Vitols, M. Murovska, S. Lejniece // Experimental Oncology. — 2011. — Т. 33, № 2. — С. 99-103. — Бібліогр.: 30 назв. — англ.
1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/138626 |
|
| Language |
en
|
|
| Relation |
Experimental Oncology
|
|
| Publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
|
|